

Oxygen nanobubbles for the reversal of hypoxia and drug delivery


NANO MEDICINE AB

Jonghoon Choi, Ph.D.

School of Integrative Engineering Chung-Ang University




THE NANOMEDICINE LAB




Ph.D. students (4): Jangsun Hwang, Yonghyun Choi, Saad Khan, Sachin Chavan
M.S. students (5): Yejin Kwon, Jaehee Jang, Kyungwoo Lee, Chanhwi Park, Dasom Kim
Undergraduate intern (2): Juhye Hong, Nayoung Kim

THE NANOMEDICINE LAB




- Nanomaterial synthesis
- Bio-conjugation of nanomaterials
- Biosensor based on nanomaterials
- Functional nanomaterials
- Drug delivery nanocarriers
- Immunologically active nanomaterials
- Theragnostic nanomaterials

Microbubble research in biomolecular imgaing




Oxygen microbubble research



https://carvertubs.com/pure-bubbles/


Why oxygen nanobubbles?




- High stability
- Controllable surface composition
- Carrier for biomolecules & drug molecules
- Cell & tissue penetration

1. Hypoxia reverse

Preparation of oxygen nanobubbles




Characterization of oxygen microbubbles




Characterization of microsize bubbles. **A.** Confocal microscopy image of microbubbles, scale bar = $20 \ \mu m$. **B.** Fluorescence microscopy image showing microbubbles, scale bar = $20 \ \mu m$. **C.** SEM image showing a microbubble, scale bar = $1 \ \mu m$. **D.** Size distribution of microbubbles calculated using ImageJ software. **E.** Concentration of microbubbles calculated in various sample groups taken from the top to the bottom of a 15 mL conical tube.

Characterization of oxygen nanobubbles




Size distribution of nanobubbles. **A.** SEM image of nanobubbles, scale bar = 100 nm. **B.** TEM image of nanobubbles, scale bar = 100 nm. **C.** NTA results for particle count and size distribution with mean size distribution in red color. **D.** DLS results of seven samples of ONBs plotted together to indicate particle size distribution.


Preparation of oxygen nanobubbles




Stability, oxygen delivery, and cytotoxicity tests. **A.** Size distribution using various dilution ratios of ONBs, obtained through an NTA. **B.** Reduction in bubble count after 30 days of storage. **C.** Increase in oxygen concentration of deoxygenated water after injection of ONBs and oxygenated DPBS. **D.** Cytotoxicity of the lipids used in synthesis of nanobubbles; ns means no significance, **** indicates P value < 0.0001. **E.** Cytotoxicity of ONBs for varying concentrations; * indicates P <0.05.


Reversal of hypoxia by oxygen nanobubbles


















H



HIF-1a downregulation induced by oxygen nanobubbles



HIF-1 α expression assay. **A.** Comparison of HIF-1 α expression in control and after the reversal of hypoxic conditions. FITC-conjugated anti-HIF-1 α antibodies were used along with DAPI staining of MDA-MB-231 cells. The reduced expression of anti-HIF-1 α is clearly observable in the fluorescence image, indicating successful degradation of HIF-1 α protein due to ONBs. Scale bars = 20 µm. **B.** HIF-1 α expression evaluated through the indirect ELISA method. The hypoxia control is the untreated sample in hypoxic conditions. Hypoxia bubble means the samples in the hypoxia chamber treated with ONBs. Normal control is an untreated sample in normal conditions. Normal bubble means the samples treated with ONBs in normal conditions; * represents P <0.05, ** represents P <0.01, ns means no significance, n = 3.

- Oxygen nanobubbles were prepared and characterized for their size, surface chemistry and oxygen delivery
- Lipid surface of bubbles can protect bubbles and also provide moiety for drug or other biomolecules
- Delivery of oxygen nanobubbles reverse the hypoxic condition of cells
- Delivery of doxorubicin drug molecules with oxygen nanobubbles provides enhanced drug effects

Acknowledgement







National Institute of Standards and Technology U.S. Department of Commerce


Department of Biomedical Engineering

Prof. Assaf A. Gilad Prof. Galit Pelled Department of Organic Chemistry Prof. Amnon Bar-Shir Department of Biomedical Engineering Prof. Weian Zhao Biosystems and Biomaterials Division Dr. Vytas Reipa




<u>School of Medicine</u> Prof. Koji Sakai Prof. Jun Tazoe















KIST, Making New History


뇌과학연구소

김홍남 박사님


최낙원 박사님

<u>생명공학부</u>

김교범 교수님









Purgo Biologics



AMOREPACIFIC



JC Bio Inc.

NANO MEDICINE LAB

Thank you!

Contact Prof. Choi for further information: Email: nanomed@cau.ac.kr